Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west Uganda by Abaasa, A et al.
TRIALS
Abaasa et al. Trials 2013, 14:33
http://www.trialsjournal.com/content/14/1/33RESEARCH Open AccessLong-term consistent use of a vaginal microbicide
gel among HIV-1 sero-discordant couples in a
phase III clinical trial (MDP 301) in rural
south-west Uganda
Andrew Abaasa1*, Angela Crook2, Mitzy Gafos2, Zacchaeus Anywaine1, Jonathan Levin1, Symon Wandiembe1,
Ananta Nanoo3, Andrew Nunn2, Sheena McCormack2, Richard Hayes4 and Anatoli Kamali1Abstract
Background: A safe and effective vaginal microbicide could substantially reduce HIV acquisition for women.
Consistent gel use is, however, of great importance to ensure continued protection against HIV infection, even with
a safe and effective microbicide. We assessed the long-term correlates of consistent gel use in the MDP 301 clinical
trial among HIV-negative women in sero-discordant couples in south-west Uganda.
Methods: HIV-negative women living with an HIV-infected partner were enrolled between 2005 and 2008, in a
three-arm phase III microbicide trial and randomized to 2% PRO2000, 0.5% PRO2000 or placebo gel arms. Follow-up
visits continued up to September 2009. The 2% arm was stopped early due to futility and the 229 women enrolled
in this arm were excluded from this analysis. Data were analyzed on 544 women on the 0.5% and placebo arms
who completed at least 52 weeks of follow-up, sero-converted or became pregnant before 52 weeks. Consistent
gel use was defined as satisfying all of the following three conditions: (i) reported gel use at the last sex act for at
least 92% of the 26 scheduled visits or at least 92% of the visits attended if fewer than 26; (ii) at least one used
applicator returned for each visit for which gel use was reported at the last sex act; (iii) attended at least 13 visits
(unless the woman sero-converted or became pregnant during follow-up). Logistic regression models were fitted to
investigate factors associated with consistent gel use.
Results: Of the 544 women, 473 (86.9%) were followed for at least 52 weeks, 29 (5.3%) sero-converted and 42
(7.7%) became pregnant before their week 52 visit. Consistent gel use was reported by 67.8%. Women aged 25 to
34 years and those aged 35 years or older were both more than twice as likely to have reported consistently using
gel compared to women aged 17 to 24 years. Living in a household with three or more rooms used for sleeping
compared to one room was associated with a twofold increase in consistent gel use.
Conclusion: In rural Uganda younger women and women in houses with less space are likely to require additional
support to achieve consistent microbicide gel use.
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Globally, HIV incidence is still high with about 2.7 mil-
lion new infections in 2010 [1]. In sub-Saharan Africa,
disproportionately more new HIV infections occur
among women than men [2]. Consistent condom use
could substantially reduce sexually acquired HIV for
women, although condom use is dependent on male co-
operation [3]. There is an urgent need for additional
HIV prevention methods that women can initiate, such
as vaginal microbicides. To date, six candidate microbi-
cides have been found to be ineffective in phase IIb or
III clinical trials [4-11]. However, the CAPRISA 004
phase IIb trial in mid-2010 provided proof of concept
for vaginal microbicides, demonstrating that tenofovir
microbicide gel reduced the risk of HIV acquisition for
women by 39% [12]. As expected with user-dependent
products such as microbicides [13], sub-analyses of the
CAPRISA 004 data demonstrated higher levels of effect-
iveness among women who adhered more strictly to
microbicide use. Effectiveness peaked at 54% in women
who reported using the microbicide in at least 80% of
sex acts [12]. Adherence to microbicides is critical in
terms of detecting an effect in clinical trials and redu-
cing the risk of HIV acquisition when an effective micro-
bicide is available [14].
Recent research (largely short-term pilot studies) has
found that adherence in microbicide studies was asso-
ciated with the acceptability of product characteristics
[15,16] and instructions for use, an understanding of
study concepts, education, partner approval [16] and age
[17]. To date, there are no reports regarding adherence
to microbicide gels among sero-discordant couples. In
this analysis we report on the long-term consistent use
of a vaginal microbicide gel among sero-discordant cou-
ples in south-west Uganda enrolled as part of the Micro-
bicides Development Programme (MDP) 301 clinical
trial. MDP 301 was an international, randomized,
double-blind, placebo-controlled parallel-group phase III
clinical trial, designed to evaluate the safety and effect-
iveness of 0.5% and 2% PRO2000 candidate microbicide
gels in preventing vaginally acquired HIV-1 infection.
Participants were enrolled at 13 clinics, across six re-
search centers in Africa (three in South Africa, one each
in Tanzania, Uganda and Zambia). In South Africa,
Tanzania and Zambia, women were enrolled without
their partners and followed up for a maximum of 52
weeks. In Uganda HIV-negative women in sero-
discordant relationships were enrolled and followed up
for a maximum of 104 weeks. The trial design and trial
results have been reported elsewhere [4,18]. In this ana-
lysis we use data from the MDP 301 trial conducted in
Masaka, south-west Uganda, to identify predictors of
long-term consistent vaginal microbicide gel use among
sero-discordant couples.Methods
The MDP 301 Masaka clinical trial site enrolled
HIV-negative healthy women who were in a known HIV
sero-discordant relationship and followed them for a
minimum of 52 weeks and a maximum of 104 weeks.
Women were enrolled between September 2005 and
August 2008 and follow-up visits continued until Septem-
ber 2009. The eligibility criteria are described in Table 1.
Details of the clinical, laboratory and pharmacy proce-
dures, data management, field activities, counseling
package and follow-up schedules are described elsewhere
[4,18,19].
After enrolment, follow-up visits were scheduled every
four weeks and were conducted at either the research
clinic or designated government health centers. Women
were initially randomized to one of the three gel groups:
0.5% PRO2000, 2% PRO2000 or placebo. Evaluation of
2% PRO2000 was stopped early on 14 February 2008 on
the recommendation of the Independent Data Monitor-
ing Committee on the basis that it was unlikely to show
benefit. By February 2008, 229 women had been rando-
mized to the 2% PRO2000 gel arm although only 37
(16.2%) had reached the study end point (either sero-
converted or reached 104 weeks of follow-up). This ana-
lysis is therefore restricted to the 0.5% PRO2000 and
placebo gel arms.
At screening, data were collected on demographic and
behavioral characteristics. Behavioral data were also col-
lected at four weekly follow-up visits, including data on
gel and condom use at the last sex act. Extended behav-
ioral data were collected at the longer clinical examin-
ation visits, which occurred at weeks 4, 12, 24, 40, 52,
64, 76, 88, 100 and 104 after enrolment. Women were
asked to bring all used and unused gel applicators to
each follow-up visit for reconciliation.
We adapted the predefined ‘consistent’ gel use criteria
used for the overall MDP 301 trial for this analysis [4].
As such, consistent gel use was defined as satisfying all
of the following three conditions: (i) reported gel use at
the last sex act for at least 92% of the 26 scheduled visits
or at least 92% of the visits attended if fewer than 26; (ii)
at least one used applicator returned for each visit for
which gel use was reported at the last sex act; (iii)
attended at least 13 (50% of the scheduled visits) of the
expected visits (unless the woman sero-converted or be-
came pregnant during follow-up). We included all gel
use data up to the point of pregnancy or sero-conver-
sion, although women who sero-converted were invited
to continue using gel and this data contributed to the as-
sessment of long-term safety [4].
Although at the longer clinical examination visits, data
were collected on gel use at every sex act in the last
week or four weeks (or if no sex was reported in the last
week), we relied on gel use at the last sex act for the
Table 1 MDP 301 Uganda: Eligibility criteria
Eligible Ineligible
Sexually active Unable or unwilling to provide a reliable method of contact for the field team
16 years old or above Likely to move permanently out of the study area within the next year
HIV negative at screening Likely to have sex more than 14 times a week on a regular basis during the course of
following up
Willing to undergo regular HIV testing and receive
the result before randomization
Using spermicides regularly
Willing to undergo regular speculum examinations
and genital infection screens
Pregnant or within six weeks postpartum at enrolment
Willing to have regular urine pregnancy tests Had a severe clinical or laboratory abnormality
Willing to use study gel as instructed Requiring referral for assessment of a clinically suspicious cervical lesion
Willing to receive health education about condoms Had treatment to the cervix, or to the womb through the cervix, within 30 days of enrolment
Willing and able to give informed consent Had known latex allergy
Participating, or having participated within 30 days of enrolment, in a clinical trial of an
unlicensed product, microbicide, barrier method or any other intervention likely to impact on
the outcome of this trial
Considered unlikely to be able to comply with the protocol
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we expect details of the last sex act to be the most ac-
curate and in the overall MDP 301 analysis, on average
gel use at the last sex act agreed with gel use at the last
10 sex acts approximately 90% of the time [20].
Statistical analysis
In this analysis, we included data from women who had
completed at least 52 weeks of follow-up or became
pregnant or sero-converted prior to the end of follow-
up. Women that became pregnant before eight weeks of
follow-up were excluded due to having just one observa-
tion data point (at the four week visit). The baseline
characteristics of trial participants who did not complete
52 weeks of follow-up and those who did were com-
pared using t-tests for continuous variables and chi-
square tests for categorical variables. We estimated the
proportion of women using gel at a given clinic visit as
the number reporting gel use divided by the number of
women attending the visit (expressed as a percentage).
Associations between consistent gel use and potential
demographic, sexual behavior and clinical determinants
were examined using odds ratios, with 95% confidence
intervals (CIs), by fitting logistic regression models. Only
factors for which the association attained statistical sig-
nificance at the 15% [21] level using a likelihood ratio
test (LRT) in an analysis adjusted only for age were con-
sidered for the multivariable model. In the multivariable
model, factors were removed from the model using a
backward elimination algorithm if removing the term
did not make the fit of the model significantly worse at
the 5% level (on an LRT). To test the robustness of the
results, we performed a sensitivity analysis by adding
data for participants who were randomized to 2%PRO2000 and had reached at least 52 weeks of follow-
up by the time the arm was discontinued.
The MDP 301 definition of consistent gel use was
informed by the fact that across all sites, the median
reported gel use at last sex act was 92% (94% in the
Ugandan dataset). In order to check the fit of the stand-
ard MDP 301 definition of consistent gel use to the
Uganda dataset, we performed sensitivity analyses based
on a median of 94% and arbitrary 90% gel use instead of
92%. Data were analyzed using Stata 10 (StataCorp, Col-
lege Station, Texas, USA).
Ethical considerations
The protocol was approved by relevant ethics commit-
tees in the UK and in each participating country, includ-
ing the Uganda Virus Research Institute Science and
Ethics committee (Protocol Number ISRCTN64716212)
and the Uganda National Council for Science and Tech-
nology (UNCST). Authorization was obtained from the
national drug regulatory authorities in each participating
country, including the Uganda National Drug Authority,
and the US Food and Drug Administration. Participants
provided written informed consent before being enrolled
into the trial.
Results
The Ugandan center screened 1,161 women and en-
rolled 840 (72.4% of those screened); 229 of the 840
(27.3%) were randomized to 2% PRO2000, 307 (36.5%)
to 0.5% PRO2000 and 304 (36.2%) to placebo. Figure 1
presents the cohort profile and shows the reasons for in-
eligibility at screening and enrolment and the number of
eligible women who decided not to enroll. As shown in
Figure 1, 67 women did not complete 52 weeks of
175 (15%) women Ineligible at screening  
111- HIV-1 positive  
49 -Pregnant  
15- Not sexually active  
1,161 couples 
screened
15 (2%) women Ineligible at enrolment  
2 Pregnant  
3 Not sexually active  
1 Having sex>14 times/week
4 Not likely to comply
4 Grade 3 abnormal lab or 
clinical event
1 Suspicious cervical lesion  
131 women didn’t return for 
enrolment  
840 enrolled 
229-women on 2% PRO2000 gel
stopped in February 2008 due to a 
likely lack of benefit  
544- women that completed at least 52 weeks of follow 
fup (or sero converted/ became pregnant before 52 
weeks) were considered for this analysis 
67 Never completed 52 week follow -up
44 Lost to follow -up
14 Pregnant before 8weeks
6 Consent withdrawn
1 Refused to continue by partner
1 Died 
1 Randomized in error (HIV+)
Figure 1 Masaka study profile.
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sons women did not complete 52 weeks of follow-up
were loss to follow-up (44), pregnancy before 8 weeks of
follow-up (14), consent withdrawn (6), refusal by partner
(1), died (1) and randomized in error (1). Consequently
the analysis includes a total of 544 women (64.8% of
those enrolled). Of these, 29 (5.3%) sero-converted, 42
(7.7%) became pregnant before 52 weeks of follow-up
and 473 (86.9%) reached 52 weeks. Of the 473 women
who completed more than 52 weeks of follow-up, 76
(16.1%) had completed 104 weeks of follow-up by the
time the study closed.
Table 2 presents the demographic, behavioral and clin-
ical characteristics of the participants. Of the women
included in this analysis, over half (60.5%) were less than
35 years old, the majority (85.1%) had attained some for-
mal education and the majority (83.1%) were un-
employed. At enrolment 58.3% of women reported the
use of a reliable method of family planning and 65.1%
reported condom use at last sex. Less than 1% of women
reported ever inserting other products intravaginally
prior to enrolment. Women reported living in house-
holds with a median of five members (IQR 4 to 7) and
with a median of two rooms (IQR 1 to 3) used for sleep-
ing. A relatively equal proportion of women reportedliving in households with 1 (34.4%), 2 (32.5%) or 3 or
more (33.1%) rooms used for sleeping.
Participants who did not complete at least 52 weeks of
follow-up were younger than those who completed at
least 52 weeks of follow-up or reached the study end
point (mean age of 28.3 vs. 32.7 years, P < 0.01). How-
ever, there were no other statistically significant differ-
ences in terms of religion, educational attainment,
employment status, family planning use and condom use
at last sex act (data not shown).
The proportion of women reporting to have used gel
at their last sex act at clinical examination visits during
follow-up ranged from 92.4% to 98.3% (Figure 2). There
was no evidence of a marked decline in the point preva-
lence of gel use over time. Across all visits in the study,
the average proportional gel use at last sex act was
92.9% (95% CI: 92.0, 93.9). Based on the predefined cri-
teria, 67.8% (95% CI: 63.7, 71.7) of women reported con-
sistent gel use during the trial. As shown in Table 2,
consistent gel use was significantly higher in older parti-
cipants, at 72.6% among 25 to 34 year olds and 71.2%
among women aged 35 years or more, compared to
47.8% among 17 to 24 year olds (P < 0.01). Consistent
gel use was also significantly higher in women who
reported living in households with three or more rooms
Table 2 Unadjusted and age-adjusted factors for reported consistent gel use
Characteristic N (%) Consistent gel users n (%) uOR (95% CI) LRT P value Age aOR (95% CI) LRT P value
All participants 544 (100) 369 (67.8)
Age group
17– 24 92 (16.9) 44 (47.8) 1 <0.01 N/A
25–34 237 (43.6) 172 (72.6) 2.9 (1.8–4.8)
≥35 215 (39.5) 153 (71.2) 2.7 (1.6–4.5)
Religion
Christian 472 (86.8) 319 (67.6) 1 0.75 1 0.54
Muslim 72 (13.2) 50 (69.4) 1.1 (0.6–1.9) 1.2 (0.7–2.1)
Level of education
None 81 (14.9) 54 (66.7) 1 0.81 1 0.52
Some education 463 (85.1) 315 (68.0) 1.1 (0.6–1.8) 1.2 (0.7–2.0)
Employment status
Employed 92 (16.9) 55 (59.8) 1 0.07 1 0.11
Unemployed 452 (83.1) 314 (69.5) 1.5 (1.0–2.4) 1.5 (0.9–2.4)
Family planning use
No 227 (41.7) 155 (68.3) 1 0.85 1 0.86
Yes 317 (58.3) 214 (67.5) 0.9 (0.7–1.4) 1.0 (0.7–1.4)
Condom use
No 190 (34.9) 123 (64.7) 1 0.26 1 0.41
Yes 354 (65.1) 246 (69.5) 1.2 (0.9–1.8) 1.2 (0.8–1.7)
Perceived sexual experience using gel
Gel made sex less enjoyable 41 (7.5) 26 (63.4) 1 0.48 1 0.27
Gel left sexual pleasure the same 317 (58.3) 209 (65.9) 1.1 (0.6–2.2) 1.2 (0.6–2.4)
Gel made sex more enjoyable 186 (34.2) 134 (72.0) 1.5 (0.7–3.2) 1.6 (0.8–3.4)
Pregnancy status
Positive 90 (16.5) 57 (63.3) 1 0.32 1 0.11
Negative 454 (83.5) 312 (68.7) 1.3 (0.8–2.0) 1.5 (0.9–2.5)
Rooms used for sleeping in at home
One 187 (34.4) 111 (59.4) 1 0.02 1 0.03
Two 177 (32.5) 120 (67.8) 1.4 (0.9–2.2) 1.2 (0.8–1.9)
Three+ 180 (33.1) 138 (76.7) 2.2 (1.4–3.5) 1.9 (1.2–3.1)
Trial arm
Placebo 275 (50.6) 183 (66.6) 1 0.52 1 0.58
PRO2000 (0.5%) 269 (49.4) 186 (69.1) 1.1 (0.8–1.6) 1.1 (0.8–1.6)
uOR, unadjusted odds ratio; CI, confidence interval; LRT, likelihood ratio test; Age aOR, age-adjusted odds ratio.
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59.4%, P < 0.01). Consistent gel use did not differ
between the trial arms, and was also not significantly
associated with religion, educational attainment, employ-
ment status, family planning use, condom use at last sex
act, perceived sexual experience of gel use or pregnancy
status (Table 2).
In the multivariable model, age group and number of
rooms used for sleeping were independently associated
with consistent gel use (Table 3). Women aged 25 to 34years old (aOR = 2.6, 95% CI: 1.6, 4.3) and 35 years or
older (aOR = 2.2, 95% CI: 1.3, 3.8) were more than twice
as likely to have reported consistently using gel than
women aged 17 to 24 years old. Living in a household
with three or more rooms used for sleeping was associated
with a twofold increase in consistent gel use (aOR = 1.9,
95% CI: 1.2, 3.0). In the sensitivity analyses using the
Uganda site median gel use of 94% and arbitrary 90% to
define consistent gel users, age group and number of
rooms used for sleeping remained the only statistically
020
40
60
80
100Percentage 
Used Gel (%) Did not use gel (%)
Used Gel (%) 94 92 94 96 94 95 95 96 98 93
Didn’t use gel (%) 6 8 6 4 6 5 5 4 2 7
527 508 470 430 473 311 248 111 82 76
4 12 24 40 52 64 76 88 100 104
Number (n)
Week Number
Figure 2 Proportions of women reporting gel use at the last sex act at each clinical visit during follow-up.
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presented).
Discussion
We have found that a high proportion of Ugandan
women in sero-discordant partnerships used the vaginal
gels consistently throughout the trial. The average
reported gel use at last sex act (92.9%) was higher than
that reported in many other trials, although comparisons
are complicated by the use of different measurements.
The COL1492 trial, reported approximately 85% of theTable 3 Adjusted factors for reported consistent gel use
Characteristic Age aOR (95% CI)
All participants
Age group
17–24 N/A
25–34
≥35
Rooms used for sleeping in at home
One 1
Two 1.2 (0.8–1.9)
Three+ 1.9 (1.2–3.1)
Trial arm
Placebo 1
PRO2000 1.1 (0.8–1.6)
Employment status
Employed 1
Unemployed 1.5 (0.9–2.4)
Pregnancy status
Positive 1
Negative 1.5 (0.9–2.5)
Age aOR, age adjusted odds ratio; CI, confidence interval; LRT, likelihood ratio test;
sleeping in at home, trial arm allocation, employment and pregnancy status.women using gel in 95% or more vaginal sex acts with
clients [10]. In the FHI trials of SAVVY in Ghana and
Nigeria, women reported using the gel during approxi-
mately 76% and 78% of sex acts respectively, in the last
7 days, based on the participant’s mean gel use across all
of their follow-up visits [5,9]. Whereas in the Carraguard
trial, in which on average 96% of the women reported
using the gel at the last sex act, an applicator stain test
to detect vaginal insertion indicated that women only
used gel on average during 42% of their sex acts [7]. In
the FHI Cellulose Sulphate trial, women reported usingLRT P value aOR (95% CI) LRT P value
1 <0.01
2.6 (1.6–4.3)
2.2 (1.3–3.8)
0.03 1 0.03
1.2 (0.8–1.9)
1.9 (1.2–3.0)
0.58 1 0.52
1.1 (0.8–1.6)
0.11 1 0.13
1.4 (0.8–2.3)
0.11 1 0.50
1.2 (0.7–1.9)
aOR, adjusted odds ratio: factors adjusted for age, number of rooms used for
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at each quarterly visit [22]. Furthermore, in the CON-
RAD Cellulose Sulphate trial, women reported using the
gel in approximately 87% of all sex acts [11] and in the
same (CONRAD) trial, adherence was slightly lower in
their Uganda site than in the other African sites. The
HPTN 035 trial reported women using gel in 81% of
their last sex acts, based on self-reported data collected
at the quarterly study visits [8]. The CAPRISA 004 trial
estimated that on average 72% (median 60%) of self-
reported sex acts in the last 30 days were covered by
two doses of gel, based on the return of used applicators
[12]. Interestingly, the average reported gel use at the
last sex act was also higher at the Uganda site than in
the overall MDP 301 trial, which was reported at 89%
[4]. The reported high average gel use in this analysis
may reflect that the women in the MDP 301 trial at
Masaka knew that their partner was HIV positive.
Known sero-discordance may go some way to explaining
differences in adherence, and effectiveness, in recent
PrEP trials [22,23]. However, the higher adherence could
also have been influenced by the fact that couples were
enrolled into the trial together, not just the women. The
evidence suggests that generally couples jointly decided
on the use of gel and women reported feeling supported
by their partners [24].
Few trials have reported on consistent gel use based
on a composite measure of self-reported gel use, return
of applicators and visit attendance, in the manner used
in this analysis. This analysis demonstrated that over
two-thirds of women reported consistently using gel for
between one and two years. While some trials have
observed an increase in gel use over time [12] and others
have observed a decrease [9], we did not observe any
changes in gel use over time. The main predictors of
consistent gel use were age and household space. Few
studies to date have reported on predictors of gel adher-
ence [16,17], although in a surrogate study [17] higher
age was associated with higher adherence to gel use.
An important finding from this analysis is that consist-
ent gel use was independently associated with the num-
ber of rooms in the household used for sleeping.
Household space has not been shown to be associated to
gel use in any previous studies and was not a predictor
of consistent gel use in the overall MDP 301 analysis
[25]. Further qualitative research is necessary to under-
standing the reason for this finding. A possible explan-
ation is that couples living in households with more
space enjoy more privacy, thereby making it easier to
apply gel before sex. None of the other variables that we
evaluated in this analysis were predictive of consistent
gel use. Our finding that educational attainment was not
significantly associated with consistent gel use is sup-
ported by previous findings [16]. It is of particularinterest that condom use at the last sex act was not
associated with consistent gel use, as gel adherence has
been linked to condom use previously [5]. There is sub-
stantial evidence that the use of vaginal microbicide gels
enhance the sexual pleasure of women and their part-
ners [26-29]. In this analysis, although consistent gel use
was slightly higher among women who reported that gel
improved sexual pleasure, the impact of the gel on sex
was not significantly associated with consistent use.
The strength of this analysis is that we have used a
composite measure of consistent gel use. However, the
main limitation is that this measure still relies on self-
reported sexual behavior and gel use data. Self-reported
data are subject to both recall and social desirability bias.
In the MDP 301 clinical trial we used a mixed methods
and triangulation model to increase the accuracy of ad-
herence and sexual behavior data [30,31]. This model
found that women were more likely to under-report sex-
ual activity, condom and gel use in the administered
questionnaires used for this analysis, when compared to
self-completed diaries and in-depth interviews. Although
this model found that most inaccuracies in the self-
reported quantitative data were unintentional, there is a
chance that consistent gel use has been overestimated in
this analysis. Conversely, the fact that the composite
measure required women to have attended at least 13 of
their expected visits and to have remained in follow-up
for at least a year, may have underestimated consistent
gel use among women in the trial. Furthermore, under-
estimation of the consistency of gel use could result
from the fact that women who completed fewer visits
were more likely to be regarded as inconsistent gel users
by the definition; for example, a woman who used gel at
the last sex act in 13 out of 15 visits would be regarded
as an inconsistent gel user compared to one who com-
pleted all the 26 visits and reported using gel at the last
sex act in 24 visits. If the women who had attended
fewer visits had completed all their scheduled visits, they
may well have been considered consistent gel users.
This study suggests that long-term consistent gel use
is high among sero-discordant rural couples in south-
west Uganda. The fact that adherence was higher in this
cohort than previously reported, suggests that factors
affecting risk reduction behavior for women in sero-
discordant relationships may be distinct from women
who are not aware of their partners’ status. The HPTN
052 trial recently demonstrated that early initiation of
antiretroviral use by HIV-infected individuals can sub-
stantially protect their HIV-uninfected sexual partners
from acquiring HIV infection, with a 96% reduction in
risk of HIV transmission [32]. Women’s preferences for
their own use of vaginal microbicides versus their posi-
tive partners’ use of treatment as prevention warrants
further research in Uganda. This is the only microbicide
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ples. However, the evidence regarding the benefit of
treatment as prevention may prevent future HIV preven-
tion trials from being able to ethically recruit sero-
discordant couples, thereby making it more difficult to
assess the use of alternative prevention modalities.
Conclusion
Our study has demonstrated that rural women in south-
west Uganda are willing and able to consistently use va-
ginal microbicide gels for a year or more. Younger
women, who are at highest risk of infection, will require
additional support to achieve consistent gel use. Add-
itional qualitative research is necessary to understand
the impact of household space on consistent gel use in
order to identify support mechanisms for women in
households with less space, to enable adherence to gel
use. These findings provide optimism regarding the
feasibility of the long-term consistent use of vaginal
microbicides if an effective microbicide is made available
for HIV prevention in the future.
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